BR112012030641A2 - métodos e composições para terapia farmacêutica oral - Google Patents

métodos e composições para terapia farmacêutica oral

Info

Publication number
BR112012030641A2
BR112012030641A2 BR112012030641A BR112012030641A BR112012030641A2 BR 112012030641 A2 BR112012030641 A2 BR 112012030641A2 BR 112012030641 A BR112012030641 A BR 112012030641A BR 112012030641 A BR112012030641 A BR 112012030641A BR 112012030641 A2 BR112012030641 A2 BR 112012030641A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
oral pharmaceutical
agents
pharmaceutical therapy
Prior art date
Application number
BR112012030641A
Other languages
English (en)
Other versions
BR112012030641B1 (pt
BR112012030641B8 (pt
Inventor
Peter Geistlich
Rolf W Pfirrmann
Original Assignee
Geistlich Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Pharma Ag filed Critical Geistlich Pharma Ag
Publication of BR112012030641A2 publication Critical patent/BR112012030641A2/pt
Publication of BR112012030641B1 publication Critical patent/BR112012030641B1/pt
Publication of BR112012030641B8 publication Critical patent/BR112012030641B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

metodos e composições para terapia farmacêutica oral. descobriu-se agora que a administração oral de agentes farmacêuticos, incluindo os agentes de transferência de n-metilol, tais como taurolidina, pode ser utilizada para proporcionar uma concentração eficaz no plasma sanguineo dos agentes para o tratamento de doenças através da liberação do agente ativo no duodemo ou jejuno de um paciente e/ou a um ph de cerca de 5,4 a cerca de 6,5. modalidades da invenção, por conseguinte, proporcionam formas de dosagem oral, composições e métodos para a administração de agentes farmacêuticos ao duodeno ou ao jejuno de um paciente, e/ou a liberação a um ph de cerca de 5,4 a cerca de 6,5.
BR112012030641A 2010-06-01 2011-06-01 Usos e composições para terapia farmacêutica oral BR112012030641B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35018310P 2010-06-01 2010-06-01
US61/350,183 2010-06-01
US37031510P 2010-08-03 2010-08-03
US61/370,315 2010-08-03
PCT/IB2011/001539 WO2011151722A2 (en) 2010-06-01 2011-06-01 Methods and compositions for oral pharmaceutical therapy

Publications (3)

Publication Number Publication Date
BR112012030641A2 true BR112012030641A2 (pt) 2016-08-16
BR112012030641B1 BR112012030641B1 (pt) 2022-05-24
BR112012030641B8 BR112012030641B8 (pt) 2022-06-14

Family

ID=45067142

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030641A BR112012030641B8 (pt) 2010-06-01 2011-06-01 Usos e composições para terapia farmacêutica oral

Country Status (10)

Country Link
US (1) US9028866B2 (pt)
EP (1) EP2575783B1 (pt)
JP (2) JP5926243B2 (pt)
CN (1) CN103118669B (pt)
AU (1) AU2011262308B2 (pt)
BR (1) BR112012030641B8 (pt)
CA (1) CA2801309C (pt)
ES (1) ES2614878T3 (pt)
HK (1) HK1183228A1 (pt)
WO (1) WO2011151722A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2850453B1 (en) * 2012-05-15 2019-09-25 Signify Holding B.V. Control of lighting devices
AU2017206750B2 (en) * 2016-01-11 2022-10-13 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
US20190381058A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Methods and compositions for treating neuroblastoma in a juvenile mammalian body
CN111936121A (zh) 2017-11-17 2020-11-13 赢创运营有限公司 制备包衣硬壳胶囊的方法
JP2021535167A (ja) * 2018-08-31 2021-12-16 コーメディクス・インコーポレーテッド 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療
WO2020234833A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Method for treating, preventing, inhibiting or reducing cytokine release
US20220323452A1 (en) 2019-05-22 2022-10-13 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh
CN111671758A (zh) * 2020-07-06 2020-09-18 长春迈灵生物工程有限公司 牛磺罗定在制备抗hiv病毒药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US6555534B1 (en) * 1998-09-11 2003-04-29 Medpointe Healthcare Inc. Method and compositions for the control or eradication of Helicobacter pylori
US6251896B1 (en) * 1999-03-24 2001-06-26 Carter-Wallace, Inc. Compositions and methods for the management of Crohn's disease
US20020098164A1 (en) * 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
JP2003507438A (ja) * 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
WO2001039763A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
US20020004502A1 (en) * 2000-01-05 2002-01-10 Redmond H. Paul Treatment of inflammatory bowel disease
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
JP5502254B2 (ja) * 2001-01-31 2014-05-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 少なくとも２種類の異なる被覆ペレット形から成る多粒子剤形
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
MXPA04012641A (es) 2002-06-21 2005-08-15 Oreal Uso de tarurina o derivados de la misma para el tratamiento de alopecia.
US20060198886A1 (en) * 2005-03-01 2006-09-07 Jenkins Richard B Medicament having coated methenamine combined with acidifier
US20100166872A1 (en) * 2005-10-21 2010-07-01 Amarjit Singh Novel improved compositions for cancer therapy
ES2318628T3 (es) * 2006-07-25 2009-05-01 Claus Herdeis Preparacion de formulaciones antimicrobianas que comprenden 7-oxa-2-tia-1,5 diazabiciclo(3.3.1)-nonan-2,2-diona.

Also Published As

Publication number Publication date
BR112012030641B1 (pt) 2022-05-24
CN103118669B (zh) 2016-01-13
HK1183228A1 (zh) 2013-12-20
JP5926243B2 (ja) 2016-05-25
AU2011262308A1 (en) 2013-01-10
EP2575783B1 (en) 2017-01-11
AU2011262308B2 (en) 2014-07-31
US20130089606A1 (en) 2013-04-11
JP2016155826A (ja) 2016-09-01
ES2614878T3 (es) 2017-06-02
CA2801309C (en) 2018-07-17
EP2575783A2 (en) 2013-04-10
BR112012030641B8 (pt) 2022-06-14
CA2801309A1 (en) 2011-12-08
JP2013527224A (ja) 2013-06-27
WO2011151722A2 (en) 2011-12-08
US9028866B2 (en) 2015-05-12
WO2011151722A3 (en) 2012-05-24
CN103118669A (zh) 2013-05-22

Similar Documents

Publication Publication Date Title
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
EA201590835A1 (ru) Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
AR105712A1 (es) Composiciones de insulina de rápida acción
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BR112016027435A2 (pt) formulação inovadora de meloxicam
HRP20192246T1 (hr) Marker za poremećaje kisele sfingomijelinaze i njegova uporaba
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/06/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2681 DE 24/05/2022 QUANTO A PRIORIDADE UNIONISTA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.